
Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study
Oligomerix Publishes Preclinical Results of Oral Alzheimer’s Drug Study Oligomerix, Inc., a pioneering clinical-stage biotechnology company focused on developing protein self-association inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, has announced the publication of a preclinical study demonstrating the…